meixatech
2 hours ago
Imidazodiazepine anticonvulsant, KRM-II-81, produces novel, non-diazepam-like antiseizure effects
Authors
Daniel E Knutson, Jodi L Smith, Xingjie Ping, Xiaoming Jin, Lalit K Golani, Guanguan Li, VVN Phani Babu Tiruveedhula, Farjana Rashid, Md Yeunus Mian, Rajwana Jahan, Dishary Sharmin, Rok Cerne, James M Cook, Jeffrey M Witkin
Publication date
2020/7/30
ACS Chemical Neuroscience 11(17): 2624-2637
Publisher
American Chemical Society
Description
The need for improved medications for the treatment of epilepsy and chronic pain is essential. Epileptic patients typically take multiple antiseizure drugs without complete seizure freedom, and chronic pain is not fully managed with current medications. A positive allosteric modulator (PAM) of a2/3-containing GABAA receptors (5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazole[1,5-a][1,4]diazepin-3-yl) oxazole or KRM-II-81 (8) is a lead compound in a series of imidazodiazepines. We previously reported that KRM-II-81 produces broad-based anticonvulsant and antinociceptive efficacy in rodent models and provides a wider margin over motoric side effects than that of other GABAA receptor PAMs. The present series of experiments was designed to fill key missing gaps in prior preclinical studies assessing whether KRM-II-81 could be further differentiated from nonselective GABAA receptor PAMs using the…
The science backing RSPI's pipeline is amazing. I looked into one of the authors of these recent papers, Rok Cerne. It appears his employment with Lilly, stopped in 2018 with no cited employers after. ??? Perhaps we could get more of an idea of what RSPI is doing by looking at the CVs of other authors of the recent publications?
Is there method to the all the apparent madness of RSPI's business model? I believe so. I strongly suspect we longs do not need to worry about being screwed. Hang in there - it could well be amazing.
loanranger
15 hours ago
Per the 9/30/23 10Q:
"As of November 14, 2023, the Company had 365,418,647, shares of common stock, $0.001 par value, issued and outstanding."
Per the Company's Transfer Agent on OTCMarkets:
Outstanding Shares as of 7/22/2024....936,463,730
Assuming that those 2 sources are credible there were ~571M shares issued between 11/14/23 and 7/22/24.
To whom? The answer to that question is likely to be in the unfiled 10K. Is that the real reason that it hasn't been filed?
The Subsequent Events section of the 9/30/23 10Q says this:
"During the period from October 1, 2023 through November 9, 2023, three convertible note holders of notes with substantially similar attributes converted $96,712 of principal, $2,923 of interest, $1,000 of conversion fees for a total of $100,635, into 67,090,000 shares of Common Stock at a conversion price, in each case, of $0.0015 per share of Common Stock."
No matter who they were issued to or why, that's a big increase.
It may be worth noting that OTC executives have been known to be lax in their Form 4 beneficial ownership filings. The 2 main players here have not filed a Form 4 since 2020. Has there been no change in their holdings since then?
LTListener
19 hours ago
Same most recent 10-q….
ResolutionRx, was organized January 11, 2023 as a wholly-owned subsidiary of RespireRx. We are also evaluating whether to organize our EndeavourRx business unit, in part or in whole, into one or more subsidiaries that would conduct R&D of our neuromodulator platform, including either or both of the AMPAkine and GABAkine programs and their related tangible and intangible assets and certain of their liabilities.
The RespireRx Group, comprised of RespireRx, ResolutionRx and EndeavourRx (and Pier, which is inactive), believes that there are advantages to separating these platforms formally into newly formed subsidiaries, including but not limited to optimizing their asset values by making them attractive to separate financing and strategic partnering channels.
10
The Company’s business development efforts (licensing, sub-licensing, joint venture and other commercial structures), if successful, would represent strategic and operational infrastructure additions, as well as cash and in-kind funding opportunities. These efforts have focused on, but have not been limited to, transacting with brand and generic pharmaceutical and biopharmaceutical companies as well as companies with potentially useful clinical development, formulation or manufacturing capabilities, significant subject matter expertise and financial resources. No assurance can be given that any transaction will come to fruition and that, if it does, the terms will be favorable to the Company.
LTListener
23 hours ago
I venture to say that we probably are all confused a bit with this entire slip to the EM market with silent communications to shareholders.
There is no logic at all to the going private commentary. There are all kinds of stakeholders with shares/warrants at .0015 and preffered/phantom shares that require major "payment events" to unlock. This is all directly in their filings. They are also seeking major funding, that is no secret in their announcements or commentary. Going private provides no liquidity for all stakeholders, no flexibility to attract talent, partners and funding. Makes zero sense.
The pipeline obviously appears tremendous. Structured with some funding to move OSA forward in Australia. DOD funding phase 2 SCI and now KRM-ll-81 exiting NIH preclinicals poised for human trials in pain and epilepsy. Big markets, Big unment needs, Big potential.
The filings also indicate the financials are a mess. Defaults everywhere. Poor management of such. To bring in major funding now, they need to resolve all these liabilities. My opinion is the value of the assets today easily dwarf these liabilities and entering possibily 3-4 human clinical trials in the next 12 months should be realistic goal.
I would love to see a merger of at least some assets with a Nasdaq company with funding available. Clear the bullshit in the filings, get new leadership to manage the business aspects and get institutional on board and provide some equity of said company to existing shareholders/stakeholders. Would it shock anyone that these assets could then sustain a 50-100+ million valuation heading into multiple human clinical trials where success yields many multiples more in valuation??
Yet here these assets sit in the belly of the OTC with no liquidity, no communication, no clarity, no logic. Time is money. Competitors are always advancing. Patents expire. Common sense thoughts I am sure all stakeholders and partners, etc consider. If anything the EM signifies some level of recognition that to move significant assets such as these forward, something different than the ho-hum past status quo on the OTC must be undertaken. At lease that is the hope.
For me, I think the tremendous potential in the assets far outweigh the liabilities and I think they have been very logical and smart with their approach to drug development. I am willing to give them time to iron out the structure and financings to move the ball forward. Clearly management and stakeholders are aligned and incentivized to do as such successfully. My opinion on this all and I accept the risk involved. Good luck to all.
THall
2 days ago
The only reason a CEO would allow their company to be placed on the Expert Market is if they wanted the price to tank. Most shareholders only have the option to sell. It doesn't take a rocket scientist to see this company is going private and shareholders are getting screwed. By moving to the EM management and insiders are assured no new shareholders can purchase shares. They know as time passes bag holders will eventually sell at .0001 for a tax loss. The only ones that can buy are out of the US so that gives the company and its insiders the opportunity to repurchase ALL the outstanding shares at deep discount without having to make an offer to shareholder to buy them out.
Shareholders would not accept a buyout offer of .0001 per share but by the company going to the EM they have no other options. The company can buy back all the shares for less than $100k now. If they made an offer to shareholders to buy them out that price would be much higher
Authorized Shares
2,000,000,000
07/22/2024
Outstanding Shares
936,463,730
StocktonCA
2 days ago
The OTC Markets has identified specific circumstances in which a Caveat Emptor designation is assigned. Once assigned, more often than not, it is not removed. The circumstances are set forth below.
Promotion/Spam Without Adequate Current Information
The security is being promoted to the public, but adequate current information about the company has not been made available to the public.
Investigation of Fraud or Other Criminal Activities
OTC Markets Group becomes aware of an investigation of fraudulent or other criminal activity involving the company, its securities, or insiders.
Suspension/Halt
A regulatory authority or an exchange has halted or suspended trading for public interest concerns (i.e., not a news or earnings halt).
Undisclosed Corporate Actions
The security or company is the subject of a corporate action, such as a reverse merger, stock split, or name change, without adequate current information being publicly available.
Unsolicited Quotes
The security has only been quoted on an unsolicited basis since it entered the public markets, and the company has not made adequate current information available to the public.
Other Public Interest Concern
OTC Markets Group has determined that there is a public interest concern regarding security. Such concerns may include but are not limited to promotion, spam, or disruptive corporate actions even when adequate current information is available.
meixatech
3 days ago
The two 2024 publications that I posted both had Lippa and Cerne as authors. I have more than 80 publications in high tier journals (i.e., I know a lot about science/publishing). Many of these medical journals have three reviewers, all of whom are highly respected in their fields. Cerne works for Eli Lilly. He participated in the research and writing of those papers in order to be an author. So, Eli Lilly paid, at least to some extent, the research and perhaps the publication fee. Possible scenario: Lippa left Eli Lilly to develop the few prospects in the RSPI pipeline using funds from stock sales and grants, thus saving development funds. Under this possible scenario, when will Lilly buy out RSPI?